Compare General Motors Company (GM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Viatris Inc — how do they compare? General Motors Company trades at $82.42 (market cap $72.17B), while Viatris Inc trades at $17.63 (market cap $20.03B). The key difference: General Motors Company is far larger — about 3.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Viatris Inc for 57 Days on average.
| GM | VTRS | |
|---|---|---|
Market Cap | $72.17B | $20.03B |
Volume | 4,900,304 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $18.27 |
52-Week Low | $55.35 | $9.74 |
Typical Hold Time | 83 Days | 57 Days |
Enterprise Value | $175.15B | $32.15B |
Dividend Yield | 0.88% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.34, up 1.67% with recent earnings beats but faces bearish technical signals. The company reported declining Q3 2026 vehicle sales of 5.5% amid EV market challenges, while maintaining strong cash flow from operations at $26.87B in 2025. Valuation metrics show a P/E of 36.72 and P/S of 0.42, with analyst consensus favoring a Buy rating and $102.08 price target.
GM's outlook is mixed with solid fundamentals offset by near-term headwinds. Investment opportunities include potential regulatory savings of $20.4B from eased fuel economy rules and consistent earnings outperformance. Key risks involve competitive pressure from Asian automakers, declining market share, and profitability pressures with net margins at 1.05%.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
